DekaBank Deutsche Girozentrale Has $100.80 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Share on StockTwits

DekaBank Deutsche Girozentrale lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 342,069 shares of the medical research company’s stock after purchasing an additional 48,760 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Thermo Fisher Scientific were worth $100,804,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of TMO. Truvestments Capital LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $29,000. Capital Advisors Ltd. LLC grew its stake in shares of Thermo Fisher Scientific by 250.0% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock worth $41,000 after acquiring an additional 100 shares during the period. Focused Wealth Management Inc bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $44,000. Farmers & Merchants Trust Co of Chambersburg PA grew its stake in shares of Thermo Fisher Scientific by 168.0% during the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock worth $55,000 after acquiring an additional 126 shares during the period. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $64,000. 88.21% of the stock is currently owned by institutional investors.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the sale, the chief financial officer now owns 40,029 shares of the company’s stock, valued at approximately $10,739,380.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares in the company, valued at approximately $1,741,606.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,775 shares of company stock worth $14,986,676. Insiders own 0.45% of the company’s stock.

TMO has been the subject of several research reports. BTIG Research increased their price target on Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. UBS Group increased their price target on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating for the company. Credit Suisse Group restated a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Finally, Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $303.17.

Shares of NYSE TMO opened at $275.17 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $208.34 and a 52 week high of $305.45. The business has a 50-day moving average of $288.15. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The company has a market cap of $110.68 billion, a P/E ratio of 24.75, a P/E/G ratio of 1.81 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, beating the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The firm had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. During the same quarter last year, the firm posted $2.75 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 12.23 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be issued a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: How Investors Can Profit from Options Trading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Coherent  PT Raised to $175.00
Coherent PT Raised to $175.00
BidaskClub Upgrades E*TRADE Financial  to Hold
BidaskClub Upgrades E*TRADE Financial to Hold
CME Group  Now Covered by Oppenheimer
CME Group Now Covered by Oppenheimer
Civista Bancshares  Upgraded to Hold at BidaskClub
Civista Bancshares Upgraded to Hold at BidaskClub
Cohu  Stock Rating Upgraded by BidaskClub
Cohu Stock Rating Upgraded by BidaskClub
Cognizant Technology Solutions  Downgraded by ValuEngine to Sell
Cognizant Technology Solutions Downgraded by ValuEngine to Sell


© 2006-2019 Ticker Report